Lilly to Invest $1B in North Carolina
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says it plans to invest over $1 billion to create a new manufacturing site in Concord, North Carolina and $500 million in a new facility in Ireland. The plant in suburban Charlotte will generate injectable products and devices to increase manufacturing capacity.
The company says the North Carolina plant will create 600 jobs for scientists, engineers and manufacturing personnel, who will use advanced technology to produce treatments and devices.
Lilly says it selected Concord because of its proximity to universities with strong STEM programs and an experienced labor force in manufacturing technology.
In 2020, the company announced a $470 million investment in Durham, which is also located in North Carolina’s Research Triangle Park.
“Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world,” said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. “Expanding our manufacturing footprint in North Carolina enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow.
Lilly says it still needs to complete county and municipal government permitting and approvals. The North Carolina project will create 500 construction jobs.
The company also announced plans Friday to invest $500 million in a new biopharmaceutical manufacturing facility in Limerick, Ireland.